Julia Grunert
Bayer HealthCare Pharmaceuticals
10 Papers
48 Citations
Julia Grunert is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Copanlisib & Aggressive lymphoma. The author has an hindex of 5, co-authored 10 publications.
Chat about Author
Papers
A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
Dan Apter,Paula Briggs,Marjo Tuppurainen,Julia Grunert,Eeva Lukkari-Lax,Sarah Rybowski,Kristina Gemzell-Danielsson +6 more
TL;DR: The LNG-IUS 8 was associated with a significantly lower 12-month discontinuation rate compared with the ENG implant; mainly because ENG implant users frequently discontinued due to increased bleeding.
57
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial
Guillem Argiles,Mark P Saunders,Fernando Rivera,Alberto Sobrero,Al B. Benson,Carmen Guillen Ponce,Stefano Cascinu,Eric Van Cutsem,Iain R. Macpherson,Dirk Strumberg,Claus-Henning Köhne,John Zalcberg,Andrea Wagner,Vittorio Luigi Garosi,Julia Grunert,Josep Tabernero,Fortunato Ciardiello +16 more
TL;DR: Regorafenib plus modified FOLFOX (mFOLFOX6) as first-line treatment in patients with metastatic CRC did not improve ORR over historical controls and did not appear to be associated with a markedly worse tolerability profile versus mFOL FOX6 alone.
49
Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma
Martin Dreyling,David Cunningham,Krimo Bouabdallah,Sarit Assouline,Eric Van Den Neste,Umberto Vitolo,Marius Giurescu,Silvia Mappa,Julia Grunert,Barrett H. Childs,Franck Morschhauser +10 more
TL;DR: The final results of this exploratory study for patients with indolent NHL or CLL treated with copanlisib are reported, finding the drug is active as a single-agent in heavily pretreated, advanced lymphoma and CLL patients with longstanding disease-related immunodeficiency.
23
Results of the Mantle Cell Lymphoma Subset from a Phase 2a Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent and Aggressive Lymphoma
David Cunningham,Pier Luigi Zinzani,Sarit Assouline,Krimo Bouabdallah,Dominique Bron,Corinne Haioun,Luigina Mollica,Marius Giurescu,Igor Gorbatchevsky,Manoel Neves,Marta M. Lemos,Julia Grunert,Florian Hiemeyer,Barrett H. Childs,Martin Dreyling +14 more
TL;DR: The final results of the MCL subset, a phase 2a study of copanlisib in patients with relapsed/refractory NHL or chronic lymphocytic leukemia, report here the final results.
9
A 12-month multicenter, randomized phase III study comparing a 13.5 mg levonorgestrel intrauterine contraceptive system with the etonogestrel subdermal contraceptive implant in women aged 18–35 years
TL;DR: The objective was to establish a baseline level of confidence that could be used as a guide for the design of future studies to investigate the role of substance abuse in the development of apes.
8